Key result
In the Korean Hypertension Cohort, 2 years of antihypertensive treatment lowered blood pressure to 130.8/78.0 mmHg, with cardiovascular events occurring in 7.5% of patients.
Why the study?
Hypertension has a significant impact on public health and medical expenses, but requires long-term follow-up of large patient cohorts to develop cardiovascular risk calculation models.
Does intensive blood pressure control (<135/85 mmHg) reduce cardiovascular events, diabetes, chronic kidney disease, and death compared to modest control (140-149 mmHg) in Korean hypertensive patients?
Cohort (n=11,083)
Yes
Does intensive blood pressure control (<135/85 mmHg) reduce cardiovascular events, diabetes, chronic kidney disease, and death compared to modest control (140-149 mmHg) in Korean hypertensive patients?
The Korean Hypertension Cohort study provides a large-scale, real-world database linking hospital and national insurance data to evaluate long-term cardiovascular outcomes of hypertension management in an Asian population.
Should not yet change BP targets in practice; leaves open whether intensive control further reduces events versus modest targets in Koreans.
BACKGROUND/AIMS: Hypertension (HT) has a significant impact on public health and medical expenses. However, HT is a chronic disease that requires the long-term follow-up of a large number of patients. METHODS: The Korean Hypertension Cohort (KHC) study aimed to develop a model for calculating cardiovascular risk in HT patients by linking and utilizing the detailed clinical and longitudinal data from hospitals and the national health insurance claim database, respectively. This cohort had a planned sample size of over 11,000 HT patients and 100,000 non-HT controls. Eligible patients were hypertensive patients, who were presenting for the first time and were diagnosed with HT as a main disease from 2006 to 2011. Long-term survival data over a period of approximately 9 years were obtained from the national health insurance claim and national health examination data. RESULTS: This cohort enrolled 11,083 patients with HT. The mean age was 58.87 ± 11.5 years, 50.5% were male, and 31.4% were never-treated HT. Of the enrolled patients, 32.9% and 37.7% belonged to the high and moderate cardiovascular risk groups, respectively. Initial blood pressures were 149.4 ± 18.5/88.5 ± 12.5 mmHg. During the 2 years hospital data follow-up period, blood pressures lowered to 130.8 ± 14.1/78.0 ± 9.7 mmHg with 1.9 ± 1.0 tablet doses of antihypertensive medication. Cardiovascular events occurred in 7.5% of the overall patients; 8.5%, 8.8%, and 4.7% in the high, moderate, and low risk patients, respectively. CONCLUSION: The KHC study has provided important information on the long-term outcomes of HT patients according to the blood pressure, comorbid diseases, medication, and adherence, as well as health behaviors and health resource use.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) conducted a cohort in Hypertension (n=11,083). Antihypertensive medication was evaluated on Cardiovascular events. In the Korean Hypertension Cohort, 2 years of antihypertensive treatment lowered blood pressure to 130.8/78.0 mmHg, with cardiovascular events occurring in 7.5% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: